RJA
ASND icon

Raymond James & Associates’s Ascendis Pharma A/S ASND Stock Holding History

Raymond James & Associates’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$538K Sell
3,601
-534
-13% -$72.1K ﹤0.01% 3066
2024
Q2 		$564K Buy
4,135
+3
+0.1% +$408 ﹤0.01% 2998
2024
Q1 		$625K Buy
4,132
+820
+25% +$117K ﹤0.01% 2916
2023
Q4 		$417K Sell
3,312
-43
-1% -$4.29K ﹤0.01% 3064
2023
Q3 		$314K Sell
3,355
-177
-5% -$16.6K ﹤0.01% 3189
2023
Q2 		$315K Sell
3,532
-49
-1% -$4.26K ﹤0.01% 3230
2023
Q1 		$384K Buy
3,581
+120
+3% +$13.7K ﹤0.01% 3077
2022
Q4 		$423K Sell
3,461
-1,019
-23% -$118K ﹤0.01% 3005
2022
Q3 		$463K Sell
4,480
-236
-5% -$22.4K ﹤0.01% 2918
2022
Q2 		$438K Sell
4,716
-218
-4% -$20.5K ﹤0.01% 2996
2022
Q1 		$579K Sell
4,934
-25,008
-84% -$2.9M ﹤0.01% 2986
2021
Q4 		$4.03M Buy
29,942
+1,398
+5% +$208K ﹤0.01% 1694
2021
Q3 		$4.55M Buy
28,544
+2,557
+10% +$350K ﹤0.01% 1555
2021
Q2 		$3.42M Buy
25,987
+1,884
+8% +$251K ﹤0.01% 1752
2021
Q1 		$3.11M Buy
24,103
+2,942
+14% +$447K ﹤0.01% 1735
2020
Q4 		$3.53M Buy
21,161
+532
+3% +$88K ﹤0.01% 1534
2020
Q3 		$3.18M Buy
20,629
+19,057
+1,212% +$2.74M ﹤0.01% 1475
2020
Q2 		$232K Buy
+1,572
New +$216K ﹤0.01% 3049
2020
Q1 		– Sell
-1,567
Closed -$218K – 3505
2019
Q4 		$218K Buy
+1,567
New +$174K ﹤0.01% 3291
2019
Q2 		– Sell
-2,895
Closed -$341K – 3639
2019
Q1 		$341K Buy
+2,895
New +$254K ﹤0.01% 2909

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Raymond James & Associates's ASND Position: Q3 2024 in Review

Raymond James & Associates reduced its Ascendis Pharma A/S (ASND) stake by 13% in Q3 2024, selling an estimated $72.1K and leaving 3,601 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Raymond James & Associates first reported a position in ASND in Q1 2019 and has held it in 20 quarters since. The position peaked at $4.55M in Q3 2021. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

  • Raymond James & Associates held 3,601 shares of Ascendis Pharma A/S worth $538K as of Q3 2024.
  • Raymond James & Associates sold 534 Ascendis Pharma A/S shares in Q3 2024, an estimated $72.1K.
  • Ascendis Pharma A/S made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3066 holding.
  • Raymond James & Associates first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 20 quarters since.
  • Raymond James & Associates's Ascendis Pharma A/S position peaked at $4.55M in Q3 2021.
  • 219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.